Your first day on retatrutide marks the beginning of a carefully supervised treatment journey. Retatrutide (LY3437943) is an investigational triple incretin receptor agonist being evaluated in clinical trials for obesity and type 2 diabetes. It has not yet received MHRA or EMA marketing authorisation and must only be taken within a registered clinical trial or approved early-access programme. This article explains what to expect on day one, how retatrutide works, which side effects are most common in the early stages, and how to manage your treatment safely from the outset.

What to Expect on Your First Day Taking Retatrutide

On day one, retatrutide is administered by subcutaneous injection in a supervised clinical setting at a low starting dose, with no immediate weight loss expected; mild nausea or reduced appetite may occur within the first few hours.

Starting a new medication can feel both hopeful and uncertain, and your first day on retatrutide is no exception. Retatrutide (also known as LY3437943) is an investigational injectable medication currently being evaluated in registered clinical trials for the management of obesity and type 2 diabetes. It is essential to understand that retatrutide has not received a marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA). It should only be taken within a registered clinical trial or an approved early-access programme under the direct oversight of a qualified investigator. You should not attempt to obtain retatrutide from online pharmacies, compounding services, or any unregulated source.

On your first day, the injection will typically be administered by a trial nurse or clinician in a supervised clinical setting. Self-injection at home is only permitted after you have received full training and your investigator has confirmed you are ready to do so. The injection is subcutaneous — given under the skin, usually in the abdomen, thigh, or upper arm. The starting dose used in phase 2 clinical trials has been low, with a gradual, pre-specified dose-escalation schedule over subsequent weeks to improve tolerability.

Physically, you may not notice dramatic changes on day one. Retatrutide does not produce immediate weight loss or blood glucose reduction; its effects build gradually over weeks of treatment. However, some individuals report early sensations such as mild nausea or reduced appetite within the first few hours following the injection. These are generally expected and relate to the drug's mechanism of action.

If you are taking insulin or a sulfonylurea alongside retatrutide, be aware of the signs of hypoglycaemia (low blood sugar) — including shakiness, sweating, confusion, and palpitations — and discuss a management plan with your clinical team before your first dose.

Retatrutide is not recommended during pregnancy or breastfeeding. If you are of childbearing potential, your trial team will advise on effective contraception. Inform your team immediately if you become pregnant or are planning a pregnancy.

Practical steps for day one:

• Keep a symptom diary from the outset

• Stay well hydrated throughout the day

• Avoid large, heavy, or high-fat meals immediately after your injection

• Have your healthcare team's and trial team's contact details readily available

• If you experience urgent or worsening symptoms, call NHS 111 for advice; call 999 or go to your nearest emergency department for severe symptoms such as persistent vomiting, severe abdominal pain, or signs of dehydration

• Report any suspected side effects to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk, and to your trial team as instructed in your participant information sheet

How Retatrutide Works in the Body

Retatrutide simultaneously activates GLP-1, GIP, and glucagon receptors, creating a synergistic effect on appetite suppression, caloric intake reduction, and energy expenditure that distinguishes it from currently approved therapies.

Retatrutide represents a novel class of medication known as a triple incretin receptor agonist. Unlike earlier agents such as semaglutide (a GLP-1 receptor agonist) or tirzepatide (a dual GIP and GLP-1 receptor agonist), retatrutide simultaneously activates three distinct hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This triple-action mechanism distinguishes it from currently approved therapies and is thought to underpin its potentially greater efficacy in weight reduction.

Each receptor plays a specific physiological role:

• GLP-1 receptor activation slows gastric emptying, reduces appetite, and stimulates insulin secretion in a glucose-dependent manner, thereby lowering blood sugar levels without causing hypoglycaemia in isolation.

• GIP receptor activation enhances insulin release and may improve fat metabolism, complementing the GLP-1 pathway.

• Glucagon receptor activation increases energy expenditure and raises hepatic glucose output; in early studies, retatrutide has also been associated with reductions in liver fat, though the precise mechanisms and long-term significance of this finding remain under investigation.

The combined stimulation of these three pathways is intended to create a synergistic effect on appetite suppression, caloric intake reduction, and metabolic rate. Because glucagon receptor activation can raise blood glucose in isolation, the simultaneous GLP-1 and GIP stimulation is essential to maintaining glycaemic safety — which is one reason why retatrutide must only be used under close medical supervision.

In a phase 2 randomised controlled trial published in the New England Journal of Medicine (Jastreboff et al., 2023), participants receiving the highest doses of retatrutide achieved a mean weight reduction of approximately 17–24% of body weight over 48 weeks, depending on dose. These findings are investigational; phase 3 trials are ongoing and regulatory review has not yet been completed. Long-term safety, including cardiovascular outcomes, has not yet been established.

Common Side Effects in the Early Stages of Treatment

The most common early side effects are gastrointestinal — particularly nausea — and are generally mild to moderate, improving as the body adjusts; urgent symptoms such as severe abdominal pain or signs of allergic reaction require immediate medical attention.

As with other incretin-based therapies, the most frequently reported side effects of retatrutide — particularly in the early stages of treatment — are gastrointestinal in nature. These effects are largely attributable to the drug's action on gastric motility and appetite-regulating pathways. Understanding what is typical can help you distinguish between expected, manageable symptoms and those that require prompt medical attention.

The most commonly reported early side effects include:

• Nausea — often the most prevalent complaint, particularly in the hours following injection; eating small, low-fat meals and staying hydrated can help

• Vomiting — less common but possible, especially if dietary advice is not followed

• Diarrhoea or constipation — changes in bowel habit are frequently reported during dose initiation

• Reduced appetite — while therapeutically desirable, this can occasionally lead to insufficient caloric intake if meals are skipped entirely

• Injection site reactions — mild redness, bruising, or discomfort at the injection site

• Fatigue or dizziness — some individuals feel lightheaded, particularly if food intake is significantly reduced

These side effects are generally mild to moderate in severity and tend to improve as the body adjusts to the medication over the first few weeks. The gradual dose-escalation protocol used in clinical trials is specifically designed to minimise their impact.

Hypoglycaemia: If you are also taking insulin or a sulfonylurea, retatrutide may increase the risk of low blood sugar. Recognise the symptoms (shakiness, sweating, confusion, palpitations) and follow your clinical team's guidance on managing a hypoglycaemic episode — typically by taking a fast-acting carbohydrate and seeking a medication review.

Biliary and gallbladder symptoms: As a class effect observed with GLP-1 receptor agonists, there is a potential signal for gallbladder-related problems. Seek urgent medical assessment if you develop right upper quadrant or upper abdominal pain, fever, or yellowing of the skin or eyes (jaundice).

Pancreatitis: Patients should seek urgent medical advice if they experience severe or persistent abdominal pain, particularly if it radiates to the back. There is no confirmed causal link between retatrutide and pancreatitis at this stage, but vigilance is warranted given the drug's pharmacological class.

Allergic reactions: Seek emergency help (call 999) if you develop signs of a serious allergic reaction, such as swelling of the face, lips, or throat, difficulty breathing, or a widespread rash.

For urgent concerns, contact NHS 111. For severe or worsening symptoms, call 999 or attend your nearest emergency department. Report all suspected adverse reactions to your trial team and to the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk).

Practical Tips for Starting Retatrutide Safely

Safe initiation requires full injection training, correct storage, eating a light low-fat meal before injecting, rotating injection sites, and informing your GP and all treating clinicians that you are commencing retatrutide.

Preparation and informed self-management are key to a safe and positive experience on your first day on retatrutide. The following practical guidance applies to participants in a clinical trial or approved early-access programme.

Before your first injection:

• Ensure you have received full training on subcutaneous injection technique from a qualified healthcare professional before attempting self-injection

• Store and handle retatrutide exactly as stated on the study pack label and per your investigator's instructions; do not use the medication if storage conditions were not maintained as directed

• Choose a consistent day of the week for your weekly injection to help establish a routine

• Inform your GP and any other treating clinicians that you are commencing retatrutide, particularly if you take other medications that may interact

• Use only medication supplied by the trial or sponsor; do not obtain retatrutide from online pharmacies, compounding services, or any unregulated source

On the day of your injection:

• Eat a light, low-fat meal beforehand rather than a large or greasy one, as this may worsen nausea

• Inject at a time of day that suits your schedule — many people prefer mornings so that any early reactions can be monitored while awake

• Rotate injection sites to reduce localised skin reactions

• Remain well hydrated throughout the day

Sharps safety:

• Dispose of used needles and syringes immediately in the sharps bin provided by your trial team

• Never share needles, syringes, or injection pens with anyone else

• Follow your local NHS arrangements for the collection or disposal of full sharps bins

Ongoing safety considerations:

• Do not adjust your dose without medical guidance

• If you are taking insulin or other glucose-lowering agents, your clinician may need to review and adjust these to reduce the risk of hypoglycaemia

• Limit alcohol, particularly in the early weeks of treatment, as it may worsen nausea and dizziness

• If you experience significant vomiting or diarrhoea, discuss 'sick day rules' for any other medicines you take (for example, certain blood pressure or diabetes medications) with your clinical team

• Keep a written or digital log of any symptoms to share with your healthcare team at your next appointment

In line with NICE guidance on shared decision-making, your healthcare team should have discussed the potential benefits, risks, and alternatives with you before commencing treatment.

What Happens After the First Few Days on Retatrutide

Gastrointestinal side effects typically begin to settle within 48 to 72 hours; meaningful appetite reduction often emerges during the first week, while measurable weight loss generally becomes apparent from weeks four to eight onwards.

The days immediately following your first retatrutide injection are an important period of adjustment. For most people, any gastrointestinal side effects experienced on day one will begin to settle within 48 to 72 hours. Retatrutide has a long half-life — estimated at approximately six days based on phase 2 pharmacokinetic data (Jastreboff et al., NEJM 2023) — meaning that drug levels rise gradually and remain relatively stable between weekly doses once a steady state is achieved (typically after approximately four to five half-lives, or around four to five weeks of weekly dosing). This gradual accumulation is one reason why titration decisions are made over several weeks rather than days.

During the first week, you may begin to notice a meaningful reduction in appetite and food cravings. This is one of the earliest therapeutic signals and reflects the drug's central and peripheral effects on hunger-regulating pathways. It is important not to interpret reduced appetite as a reason to skip meals entirely; maintaining adequate nutrition — including sufficient protein and micronutrient intake — remains essential throughout treatment.

Over the first four to eight weeks, your clinical team will monitor you according to the trial protocol schedule. This typically includes:

• Body weight — to assess early response to treatment

• Blood glucose levels — particularly if you have type 2 diabetes or are taking glucose-lowering medicines

• Renal and hepatic function — as part of routine safety monitoring

• Gastrointestinal symptom burden — to determine whether dose escalation can proceed as planned

If side effects remain troublesome beyond the first week, your clinician may delay dose escalation or provide additional supportive measures. It is important to attend all scheduled follow-up appointments and to contact your trial team promptly if you experience any unexpected or worsening symptoms.

Based on phase 2 trial data, meaningful weight loss typically becomes apparent from weeks four to eight onwards, with continued progress over several months at higher doses. These findings remain investigational pending the completion of phase 3 trials and regulatory review. Patience and consistent engagement with your healthcare team are central to achieving the best possible outcomes from retatrutide treatment.

Remember: report any suspected side effects to your trial team and to the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Frequently Asked Questions